Literature DB >> 30116953

The pivotal role of microRNA-21 in osteoclastogenesis inhibition by anthracycline glycoside aloin.

Radha Madhyastha1, Harishkumar Madhyastha2, Yutthana Pengjam3, Queen Intan Nurrahmah2, Yuichi Nakajima2, Masugi Maruyama2.   

Abstract

Osteopenic disorders such as osteoporosis and rheumatoid arthritis are characterized by excessive bone resorption by osteoclasts relative to bone formation by osteoblasts. MicroRNAs are emerging as key players in bone remodeling, modulating the functions of both osteoblasts and osteoclasts. Among them, miR-21 is highly expressed in osteoclast precursors and is known to regulate genesis, differentiation, and apoptosis of osteoclasts. The pro-osteoclastogenic nature of miR-21 makes it a potential candidate as a therapeutic target to treat bone disorders. We had previously demonstrated that anthroglycoside aloin derived from Aloe vera was effective in promoting osteoblastogenesis and inhibiting osteoclastogenesis. The present study investigated the role of miR-21 in aloin's inhibitory effect on osteoclast differentiation. Aloin effectively suppressed receptor activator of nuclear factor kappa-B (NFĸB) ligand (RankL)-induced miR-21 expression via repression of NFĸB activation. MiR-21 suppression resulted in upregulation of osteoclast suppressor programmed cell death protein 4 (PDCD4), and downregulation of osteoclast marker cathepsin K. Knockdown or gain-of-function studies revealed that miR-21 was pivotal to aloin's inhibitory effect on osteoclastogenesis. This study also highlights the dynamic potential of aloin as a therapeutic agent to treat osteopenic disorders.

Entities:  

Keywords:  Aloin; MicroRNA-21; NFĸB; Osteoclastogenesis inhibition

Mesh:

Substances:

Year:  2018        PMID: 30116953     DOI: 10.1007/s11418-018-1237-3

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  34 in total

1.  miR-21 modulates the ERK-MAPK signaling pathway by regulating SPRY2 expression during human mesenchymal stem cell differentiation.

Authors:  Yang Mei; Chunjing Bian; Jing Li; Zhijian Du; Hong Zhou; Zhuo Yang; Robert C H Zhao
Journal:  J Cell Biochem       Date:  2013-06       Impact factor: 4.429

2.  Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis.

Authors:  Toshifumi Sugatani; Keith A Hruska
Journal:  J Cell Biochem       Date:  2013-06       Impact factor: 4.429

3.  NFkappaB activation is essential for miR-21 induction by TGFβ1 in high glucose conditions.

Authors:  Radha Madhyastha; HarishKumar Madhyastha; Yutthana Pengjam; Yuichi Nakajima; Sayuri Omura; Masugi Maruyama
Journal:  Biochem Biophys Res Commun       Date:  2014-08-14       Impact factor: 3.575

Review 4.  Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.

Authors:  Sakae Tanaka; Kozo Nakamura; Naoyuki Takahasi; Tatsuo Suda
Journal:  Immunol Rev       Date:  2005-12       Impact factor: 12.988

Review 5.  The molecular understanding of osteoclast differentiation.

Authors:  Masataka Asagiri; Hiroshi Takayanagi
Journal:  Bone       Date:  2006-11-13       Impact factor: 4.398

6.  Five freely circulating miRNAs and bone tissue miRNAs are associated with osteoporotic fractures.

Authors:  Claudine Seeliger; Katrin Karpinski; Alexander T Haug; Helen Vester; Andreas Schmitt; Jan S Bauer; Martijn van Griensven
Journal:  J Bone Miner Res       Date:  2014-08       Impact factor: 6.741

7.  Impaired micro-RNA pathways diminish osteoclast differentiation and function.

Authors:  Toshifumi Sugatani; Keith A Hruska
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

8.  Tumor necrosis factor α suppresses the mesenchymal stem cell osteogenesis promoter miR-21 in estrogen deficiency-induced osteoporosis.

Authors:  Nan Yang; Guang Wang; Chenghu Hu; Yuanyuan Shi; Li Liao; Songtao Shi; Yan Cai; Shuli Cheng; Xi Wang; Yali Liu; Liang Tang; Yin Ding; Yan Jin
Journal:  J Bone Miner Res       Date:  2013-03       Impact factor: 6.741

Review 9.  Modulation of osteoclast differentiation by local factors.

Authors:  T Suda; N Udagawa; I Nakamura; C Miyaura; N Takahashi
Journal:  Bone       Date:  1995-08       Impact factor: 4.398

Review 10.  Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation.

Authors:  Jing An; Hao Yang; Qian Zhang; Cuicui Liu; Jingjing Zhao; Lingling Zhang; Bo Chen
Journal:  Life Sci       Date:  2016-01-18       Impact factor: 5.037

View more
  6 in total

Review 1.  Implications of microRNA 21 and its involvement in the treatment of different type of arthritis.

Authors:  Durairaj Sekar
Journal:  Mol Cell Biochem       Date:  2020-11-02       Impact factor: 3.396

Review 2.  Regulation of osteoclast-mediated bone resorption by microRNA.

Authors:  Ling Ji; Xinyi Li; Shushu He; Song Chen
Journal:  Cell Mol Life Sci       Date:  2022-05-10       Impact factor: 9.261

3.  MicroRNA 21 Elicits a Pro-inflammatory Response in Macrophages, with Exosomes Functioning as Delivery Vehicles.

Authors:  Radha Madhyastha; Harishkumar Madhyastha; Queen Intan Nurrahmah; Bethasiwi Purbasari; Masugi Maruyama; Yuichi Nakajima
Journal:  Inflammation       Date:  2021-01-26       Impact factor: 4.092

Review 4.  Pharmacological Update Properties of Aloe Vera and its Major Active Constituents.

Authors:  Marta Sánchez; Elena González-Burgos; Irene Iglesias; M Pilar Gómez-Serranillos
Journal:  Molecules       Date:  2020-03-13       Impact factor: 4.411

5.  MicroRNA-21 affects mechanical force-induced midpalatal suture remodelling.

Authors:  Mengying Li; Zijie Zhang; Xiuge Gu; Ye Jin; Cheng Feng; Shuangyan Yang; Fulan Wei
Journal:  Cell Prolif       Date:  2019-11-12       Impact factor: 6.831

Review 6.  The roles of miRNA, lncRNA and circRNA in the development of osteoporosis.

Authors:  Yang Yang; Wang Yujiao; Wang Fang; Yuan Linhui; Guo Ziqi; Wei Zhichen; Wang Zirui; Wang Shengwang
Journal:  Biol Res       Date:  2020-09-16       Impact factor: 5.612

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.